Effects of MCI-186 on intracellular calcium ion concentration and membrane fluidity of hippocampal neurons in a rat model of Alzheimer's disease

Neural Regeneration Research

Volumn 6, Issue 29, 2011, Pages 2245-2250

  Yu, Ming ^a   Qin, Lei ^b   Wang, Zhao ^c   Lu, Xiaohong ^c   Zhu, Ying ^a   Leng, Wenhui ^a   Wang, Xuan ^c  

^a AFFILIATED HOSPITAL OF JIANGSU UNIVERSITY   (China)

^b NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^c JIAMUSI UNIVERSITY   (China)

Author keywords

Alzheimer's disease; Calcium ion; Learning; MCI 186; Memory; Neural regeneration; Neurodegenerative diseases

Indexed keywords

CALCIUM ION; NORPHENAZONE;

ALZHEIMER DISEASE; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN NERVE CELL; BRAIN REGION; CALCIUM CELL LEVEL; CELL MEMBRANE FLUIDITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; ESCAPE BEHAVIOR; HIPPOCAMPAL NEURON; HIPPOCAMPUS; LATENT PERIOD; LEARNING; LOW DRUG DOSE; MALE; MEMORY; NEUROPROTECTION; NONHUMAN; RAT; RESPONSE TIME; SHAM PROCEDURE; VISCOSITY;

EID: 81755169847     PISSN: 16735374     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.1673-5374.2011.29.001     Document Type: Article

References (36)

1. Fratiglioni L, Mangialasche F, Qiu C. Brain aging: lessons from community studies. Nutr Rev. 2010;68 (Suppl 2):S119-127.
2. Sultana R, Butterfield DA. Oxidatively modified, mitochondria-relevant brain proteins in subjects with Alzheimer disease and mild cognitive impairment. J Bioenerg Biomembr. 2009;41(5): 441-446.
3. 2+ homeostasis disorders. Molecules. 2010; 15(10):7167-7187.
4. León R, Marco-Contelles J. A step further towards multitarget drugs for Alzheimer and neuronal vascular diseases: targeting the cholinergic system, amyloid-β aggregation and Ca(2+) dyshomeostasis. Curr Med Chem. 2011;18(4):552-576.
5. Unno Y, Katayama M, Shimizu H. Does functional outcome in acute ischaemic stroke patients correlate with the amount of free-radical scavenger treatment? A retrospective study of edaravone therapy. Clin Drug Investig. 2010;30(3):143-155.
6. Takahashi R. Edaravone in ALS. Exp Neurol. 2009;217(2):235-236.
7. Yu M, Li SJ, Leng WH, et al. Protective effect of MCI-186 on oxidative damage in a cell model of Alzheimer's disease. Neural Regen Res. 2010;5(16):1226-1230.
8. Yu M, Bao XQ. Effects of MCI-186 on the expression of gene NF-κB P65 in the PC12 cells induced by Aβ25-35. Zhongguo Laonian Xue Zazhi. 2008;28(11):2199-2201.
9. Yu M, Zhang XL, Leng WH, et al. Neuroprotective effects of MCI-186 on the PC12 cells induced by Aβ25-35. Jiangsu Yiyao. 2009;35(11):1317-1320.
10. Toescu EC, Vreugdenhil M. Calcium and normal brain ageing. Cell Calcium. 2010;47(2):158-164.
11. Burke SN, Barnes CA. Senescent synapses and hippocampal circuit dynamics. Trends Neurosci. 2010;33(3):153-161.
12. Bezprozvanny I. Calcium signaling and neurodegenerative diseases. Trends Mol Med. 2009;15(3):89-100.
13. Kahraman S, Zup SL, McCarthy MM, et al. GABAergic mechanism of propofol toxicity in immature neurons. J Neurosurg Anesthesiol. 2008;20(4):233-240.
14. 2+ channels: a single molecular switch for long-term potentiation/ long-term depression-like plasticity and activity-dependent metaplasticity in humans. J Neurosci. 2010;30(18):6197-6204.
15. Seoane A, Massey PV, Keen H, et al. L-type voltage-dependent calcium channel antagonists impair perirhinal long-term recognition memory and plasticity processes. J Neurosci. 2009; 29(30):9534-9544.
16. Yu JT, Chang RC, Tan L. Calcium dysregulation in Alzheimer's disease: from mechanisms to therapeutic opportunities. Prog Neurobiol. 2009;89(3):240-255.
17. Supnet C, Bezprozvanny I. The dysregulation of intracellular calcium in Alzheimer disease. Cell Calcium. 2010;47(2):183-189.
18. Nimmrich V, Ebert U. Is Alzheimer's disease a result of presynaptic failure? Synaptic dysfunctions induced by oligomeric beta-amyloid. Rev Neurosci. 2009;20(1):1-12.
19. Berridge MJ. Calcium hypothesis of Alzheimer's disease. Pflugers Arch. 2010;459(3):441-449.
20. Cerella C, Diederich M, Ghibelli L. The dual role of calcium as messenger and stressor in cell damage, death, and survival. Int J Cell Biol. 2010;2010:546-163.
21. Tõugu V, Tiiman A, Palumaa P. Interactions of Zn(ii) and Cu(ii) ions with Alzheimer's amyloid-beta peptide. Metal ion binding, contribution to fibrillization and toxicity. Metallomics. 2011;3(3): 250-261.
22. Adibhatla RM, Hatcher JF. Lipid oxidation and peroxidation in CNS health and disease: from molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal. 2010;12(1): 125-169.
23. MacManus A, Ramsden M, Murray M, et al. Enhancement of (45)Ca(2+) influx and voltage-dependent Ca(2+) channel activity by beta-amyloid-(1-40) in rat cortical synaptosomes and cultured cortical neurons. Modulation by the proinflammatory cytokine interleukin-1beta. J Biol Chem. 2000;275(7):4713-4718.
24. Yamin G. NMDA receptor-dependent signaling pathways that underlie amyloid beta-protein disruption of LTP in the hippocampus. J Neurosci Res. 2009;87(8):1729-1736.
25. Small DH, Gasperini R, Vincent AJ, et al. The role of Abeta-induced calcium dysregulation in the pathogenesis of Alzheimer's disease. J Alzheimers Dis. 2009;16(2):225-233.
26. Demuro A, Parker I, Stutzmann GE. Calcium signaling and amyloid toxicity in Alzheimer disease. J Biol Chem. 2010;285(17): 12463-12468.
27. Shelat PB, Chalimoniuk M, Wang JH, et al. Amyloid beta peptide and NMDA induce ROS from NADPH oxidase and AA release from cytosolic phospholipase A2 in cortical neurons. J Neurochem. 2008;106(1):45-55.
28. Green KN. Calcium in the initiation, progression and as an effector of Alzheimer's disease pathology. J Cell Mol Med. 2009; 13(9A):2787-2799.
29. Liu D, Pitta M, Lee JH, et al. The KATP channel activator diazoxide ameliorates amyloid-β and tau pathologies and improves memory in the 3xTgAD mouse model of Alzheimer's disease. J Alzheimers Dis. 2010;22(2):443-457.
30. Shirwany NA, Payette D, Xie J, et al. The amyloid beta ion channel hypothesis of Alzheimer's disease. Neuropsychiatr Dis Treat. 2007;3(5):597-612.
31. [] The Ministry of Science and Technology of the People's Republic of China. Regulations for the Administration of Affairs Concerning Experimental Animals. 1988-10-31.
32. Peterson GM, Williams LR, Varon S, et al. Loss of GABAergic neurons in medial septum after fimbria-fornix transection. Neurosci Lett. 1987;76(2):140-144.
33. Huang J, Chen YJ, Bian WH, et al. Unilateral amyloid-beta25-35 injection into the rat amygdala increases the expressions of aberrant tau phosphorylation kinases. Chin Med J (Engl). 2010; 123(10):1311-1314.
34. Liu YJ, Zhu QF. Effect of clausenamide on hippocampal neuron apoptosis induced by sodium nitroprusside. Neural Regen Res. 2007;2(1):33-37.
35. Fabiato A, Fabiato F. Calculator programs for computing the composition of the solutions containing multiple metals and ligands used for experiments in skinned muscle cells. J Physiol.1979;75(5):463-505.
36. Lin KC, Nie SQ, Be HQ, et al. Research on membrane fluidity of ascites cells with fluorescence probe DPH. Prog Biochem Biophys. 1982;9(6):32-36.